Elevar Therapeutics Inc. and Hengrui Pharmaceuticals Co. Ltd.’s licensing deal for camrelizumab (SHR-1210; Airuika in China) will add the PD-1 antibody to Elevar’s liver cancer armory for pairing with rivoceranib, its tyrosine kinase inhibitor on the brink of U.S. FDA review.
Elevar Therapeutics Inc. and Hengrui Pharmaceuticals Co. Ltd.’s licensing deal for camrelizumab (SHR-1210; Airuika in China) will add the PD-1 antibody to Elevar’s liver cancer armory for pairing with rivoceranib, its tyrosine kinase inhibitor on the brink of U.S. FDA review.
HLB Co. Ltd. is ready to take half of the liver cancer treatment market with its potential first-line treatment, rivoceranib, currently undergoing U.S. FDA review, company chairman Jin Yang-gon said, backed by positive survival data that beat out competitors by three months.
China’s Jiangsu Hengrui Pharmaceuticals Co. Ltd. is launching a new biotech company called Luzsana Biotechnology that will develop and commercialize Hengrui assets in the U.S., Europe and Japan. A wholly owned subsidiary of Hengrui, Luzsana, which means “healing light,” will develop innovative products from Hengrui’s pipeline.
China’s Jiangsu Hengrui Pharmaceuticals Co. Ltd. is launching a new biotech company called Luzsana Biotechnology that will develop and commercialize Hengrui assets in the U.S., Europe and Japan. A wholly owned subsidiary of Hengrui, Luzsana, which means “healing light,” will develop innovative products from Hengrui’s pipeline.
HONG KONG – After inking a recent deal with China’s Jiangsu Hengrui Medicine Co. Ltd., South Korea’s Crystalgenomics Inc. is celebrating its 20th anniversary by seeking more partners to further develop its anti-PD-1 inhibitor pipeline.
HONG KONG – After inking a recent deal with China’s Jiangsu Hengrui Medicine Co. Ltd., South Korea’s Crystalgenomics Inc. is celebrating its 20th anniversary by seeking more partners to further develop its anti-PD-1 inhibitor pipeline.